Ibuprofen to reduce acute inflammation after one-stage non-surgical periodontal therapy

Efficacy Of Ibuprofen In Reducing Acute Inflammatory Response Following One Stage Non- Surgical Periodontal Therapy (A Randomized Clinical Trial )

This trial will test whether short-term ibuprofen lowers acute inflammatory markers (hs-CRP, ProCT, IL-6) in adults with generalized periodontitis after one-stage non-surgical periodontal therapy.

Quick facts

• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: University of Baghdad (Academic / other)
• Locations: 1 site (Baghdad)
• Trial ID: NCT07459049 on ClinicalTrials.gov

What this trial studies

Participants receive baseline clinical exams, demographic data collection, standardized oral hygiene instructions, and baseline blood samples before scaling. One week later full‑mouth root surface debridement is performed in a single session by one periodontist, with the test group given 400 mg ibuprofen one hour before treatment and then three times daily for three days while the control group receives no ibuprofen. Blood biomarkers (hs-CRP, ProCT, IL‑6) are measured at baseline, one hour after therapy, and one week after therapy to compare acute inflammatory responses. Procedure time is recorded and standardized instruments and breaks are used to reduce operator and patient variability.

Who should consider this trial

Good fit: Systemically healthy adults over 18 with generalized unstable periodontitis, at least 20 teeth, and pocket depths ≥4 mm (smokers allowed) are the intended participants.

Not a fit: People with NSAID allergy, current systemic anti-inflammatory or antibiotic use, pregnancy or lactation, severe hepatic/renal/cardiac disease, bleeding disorders, or active high‑risk infections (TB, hepatitis B, HIV) are not likely to benefit or be eligible.

Why it matters

Potential benefit: If successful, short-term ibuprofen could reduce the immediate systemic inflammatory response after periodontal cleaning and lower short-term inflammation markers.

How similar studies have performed: Previous studies of NSAIDs including ibuprofen have shown some short-term reductions in periodontal inflammation and systemic markers but results have been mixed and not uniformly conclusive.

Eligibility criteria

Inclusion Criteria:

1. systemically healthy patients.
2. having a minimum of 20 teeth.
3. Generalized unstable periodontitis.
4. Pocket depth \[≥ 4 mm\].
5. All included participants should be adults aged more than 18 years .
6. smokers and non smokers

Exclusion Criteria:

1. Allergy or hypersensitivity to Ibuprofen or other NSAIDs.
2. current systemic anti-inflammatory or antibiotic therapy (\<3 months).
3. peptic ulcer disease.
4. recent periodontal therapy (\<3 months).
5. Asthma.
6. Renal impairment .
7. Hepatic impairment.
8. Severe cardiac disease (heart failure, hypertension (.
9. Bleeding disorders (e.g., hemophilia) or patients taking anticoagulants .
10. Any participant who had known or suspected high risk for tuberculosis, hepatitis B or HIV infections.
11. pregnant or lactating females.
12. those being unable to provide written informed consent.

Where this trial is running

Baghdad

• College of Dentistry, University of Baghdad — Baghdad, Iraq (Recruiting)

Study contacts

• Study coordinator: Nabaa Ismail Ibrahim, B.D.S

Conditions Periodontitis; Ibuprofen; Acute inflammatory response; One stage periodontal therapy; Non-surgical periodontal therapy